Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 3, Multicenter, Randomized, Efficacy Accessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Failed Anti-TNF therapy

This study will compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease who have failed anti-TNF therapy.
Zvjezdana Stella Sever Chroneos at zchroneos1@pennstatehealth.psu.edu or 717-531-8259
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04524611
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of CD for at least 3 months
Demonstrated intolerance or inadequate response to one or more anti TNF therapies
Laboratory values meeting protocol criteria
CDAI score of 220-450 at Baseline
Exclusion Criteria:
No history of UC
No known complications of CD
No systematic bowel strictures
No history of malignancy
No history of allergic reactions to the products in the same class
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA